Theranostics on the ASX in 2026, where Telix, Clarity, Radiopharm, Cyclopharm and OncoSil stand as radiopharmaceuticals move from trials to sales.

Radiopharmaceuticals are the 2026 biotech area closest to sales for ASX investors. How cancer vaccines, gene editing and AI drug discovery compare.

Recce Pharmaceuticals' synthetic antibiotic R327, what its Phase 3 trials have and have not shown, the Arrotex licence, and the cash, debt and AGM.

Island Pharmaceuticals (ASX ILA) is taking galidesivir to the FDA for Marburg. We cover the monkey data, the Ebola outbreak, the timeline and the cash.

Clever Culture Systems (ASX CC5) sells an AI plate reader to AstraZeneca and Pfizer. Samso reads the customer data, the PSC Biotech deal and the cash.

The FDA approval process explained for drugs, devices and tests. What approval gives a company, what it does not, and the ASX record.

Samso counts 25 ASX companies whose main product is AI. Together they are worth A$2.2 billion, and most are small caps.

Cleo Diagnostics (ASX COV) plans an FDA submission for its ovarian cancer blood test in the first half of 2027. Samso reads the evidence and the cash.

Blood tests for early cancer detection are now sold in Australia. Samso reviews the trial evidence and BCAL Diagnostics (ASX: BDX), its sales and funding.

Starpharma trades at 80 cents against 8.6 cents sixteen months ago, and the chart looks like an uptrend. This Chart Read tests that impression against the measures. The moving averages agree. ADX at 14.6 says the move stopped being decisive in July. One session in September 2025 did 26 per cent of the whole two-year move on 99.7 times normal volume.